India, Nov. 14 -- Novartis (NVS,NOVN.SW) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx (secukinumab) for adolescents aged 12 years and older with active moderate-to-severe hidradenitis suppurativa who have not responded adequately to conventional systemic therapies.
The positive opinion marks an important step toward expanding treatment options for younger patients living with the chronic inflammatory skin disease. A final decision from the European Commission is expected within the next two months.
If approved, Cosentyx would become the only IL-17A inhibitor authorized in Europe for adolescent HS patients and the first innovative biologic trea...